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Abstract
Background: Outreach facilitation has been proven successful in improving the adoption of
clinical preventive care guidelines in primary care practice. The net costs and savings of delivering
such an intensive intervention need to be understood. We wanted to estimate the proportion of
a facilitation intervention cost that is offset and the potential for savings by reducing inappropriate
screening tests and increasing appropriate screening tests in 22 intervention primary care practices
affecting a population of 90,283 patients.
Methods: A cost-consequences analysis of one successful outreach facilitation intervention was
done, taking into account the estimated cost savings to the health system of reducing five
inappropriate tests and increasing seven appropriate tests. Multiple data sources were used to
calculate costs and cost savings to the government. The cost of the intervention and costs of
performing appropriate testing were calculated. Costs averted were calculated by multiplying the
number of tests not performed as a result of the intervention. Further downstream cost savings
were determined by calculating the direct costs associated with the number of false positive test
follow-ups avoided. Treatment costs averted as a result of increasing appropriate testing were
similarly calculated.
Results:  The total cost of the intervention over 12 months was $238,388 and the cost of
increasing the delivery of appropriate care was $192,912 for a total cost of $431,300. The savings
from reduction in inappropriate testing were $148,568 and from avoiding treatment costs as a
result of appropriate testing were $455,464 for a total savings of $604,032. On a yearly basis the
net cost saving to the government is $191,733 per year (2003 $Can) equating to $3,687 per
physician or $63,911 per facilitator, an estimated return on intervention investment and delivery
of appropriate preventive care of 40%.
Conclusion: Outreach facilitation is more expensive but more effective than other attempts to
modify primary care practice and all of its costs can be offset through the reduction of
inappropriate testing and increasing appropriate testing. Our calculations are based on conservative
assumptions. The potential for savings is likely considerably higher.
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Background
A randomized, controlled field trial of a multifaceted
intervention to improve preventive care tailored to the
needs of participating family practices was conducted in
Southern Ontario and delivered by nurses trained in the
facilitation of prevention. This report is a cost-conse-
quences analysis of the intervention. Specifically, it pro-
vides information about the cost of the outreach
facilitator intervention and money saved the health care
system as a result of reducing inappropriate and increas-
ing appropriate preventive screening tests.
Improving preventive performance is both important and
necessary. There is substantial room to improve rates of
appropriate preventive practice [1]. The Canadian Task
Force on the Periodic Health Examination [2,3] has estab-
lished guidelines for the delivery of preventive care that
are supported by clinical evidence as effective in decreas-
ing the impact of disease. However, evidence-based guide-
lines are not self-implementing [4-6]. Changing
physicians' long-held patterns of behaviour and the envi-
ronments in which they work is essential yet complex and
difficult. Unless the barriers to change can be overcome
and actions taken to put preventive care guidelines into
practice, evidence-based guideline development efforts
will be wasted and the quality of preventive care will not
improve [7].
Several reviews have focussed on the effectiveness of dif-
ferent interventions for implementing guidelines and
improving care [5,6,8-12]. Multi-faceted outreach facilita-
tion interventions employing trained individuals who
meet with providers in their practice setting to provide
information and assist the practice in implementing evi-
dence-based guidelines have been shown to be more
effective than single interventions such as guideline dis-
semination efforts or physician prompts [10-14]. Tailor-
ing interventions to the requirements of the practice has
also been proposed as important in supporting practice
changes and in attaining more successful and sustained
outcomes in preventive care performance as compared to
interventions that are fixed and lack this flexibility [15-
19]. Given the diversity of practice environments, it is
unlikely that "one size fits all" approaches to improving
preventive care will be able to address the needs of all pro-
viders and their patients [20,21].
Successful interventions designed to improve compliance
with evidence-based guidelines for preventive care could
have an important influence on the health of Canadians.
In addition, interventions designed to reduce the ordering
of inappropriate tests in delivering preventive care have
the potential to offset some of the intervention costs.
Economic evaluations of outreach facilitation
By its nature, outreach facilitation is multifaceted. In the
United Kingdom and the United States specially trained
nurse facilitators organized preventive care in busy practi-
tioners' offices through outreach visits and using
approaches such as academic detailing, chart audit and
feedback for the prevention and early detection of cardio-
vascular disease and cancer [22,23]. Very few evaluations
of outreach facilitation have studied the costs of deliver-
ing these interventions. The Cochrane Effective Practice
and Organization of Care Group has concluded that out-
reach visits are effective, however, cost-effectiveness needs
to be determined [24]. Soumerai and Avorn have sug-
gested that the savings from outreach facilitation may out-
weigh the costs if the intervention is targeted at
inappropriate and costly practice behaviour [25,26].
Cockburn and colleagues conducted a randomized con-
trolled trial in which the effectiveness of three approaches
to marketing a quit smoking intervention kit to physicians
was evaluated [27]. They conclude that educational out-
reach facilitators do not appear to be cost effective strate-
gies for distributing smoking interventions. The actual use
of the kit by the physicians for their smoking patients did
not differ significantly across groups. However, there was
a trend toward higher use in the facilitation group for one
of the components of the kit as compared to those who
received the kit by courier or standard mail.
Conversely, McCowan et. al. conducted a randomized
controlled trial to examine the effect of a facilitator inter-
vention on the management of children with asthma by
family physicians [28]. They found that the facilitator
intervention reduced asthma care costs in the intervention
group as compared to the control resulting in an overall
net saving of 12,000 (U.K. 1991) pounds or one pound
less per child per annum. The facilitator accomplished
this by inserting guidelines for the management of asthma
into intervention practices' case records. The authors esti-
mate that the net savings to the health system would
recoup the facilitator's salary at 1991 rates.
The literature on the costs of outreach facilitation is lim-
ited. It can be argued that facilitation is a costly interven-
tion [27]. However, a costly intervention that achieves
success may be preferred to a cheaper one that demon-
strates very little or has no lasting effect. More research on
the costs of successful facilitation and other effective alter-
native interventions to outreach facilitation is necessary.
Intervention description
The nurse facilitation in our study was a tailored multifac-
eted approach to getting evidence into action. Three nurse
facilitators focused on the educational, attitudinal and
organizational barriers to change in the practice settingBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
Page 3 of 15
(page number not for citation purposes)
and tailored a multi-component intervention to the spe-
cific needs of the practice [22,23,29,30,17,31-34]. The
facilitators completed a 30-week intensive training pro-
gram before being assigned to intervention practices. The
training covered an orientation session, medical office
computer systems, medical practice management, preven-
tion in primary care, evidence-based medicine, and facili-
tation and audit skills development. Approximately 28
hours per week were spent in training and 7 hours per
week in preparation and planning. Six of the 30 weeks of
training were spent applying skills in a primary care office
setting.
The intervention period was 18 months ending December
1998. During this period each intervention practice was
visited an average of 33 times (range 21 to 50) at an aver-
age visit length of one hour 45 minutes. The facilitators
delivered primarily three intervention strategies to
improve preventive care: chart audit and feedback, educa-
tional consensus building, and reminder systems. They
discussed the strategies with the physicians and practice
staff, working with them to adapt the strategies to the
practice needs and wishes. All 22 of the intervention prac-
tices participated in an initial audit and received feedback
on preventive care practice patterns. Twenty practices
requested subsequent audits and analyses of data to fol-
low their rates of performance. All of the practices were
involved in meetings with the facilitator to identify oppor-
tunities for improvement, assess needs, receive and dis-
cuss critically appraised evidence from the literature for
the preventive maneuvers, and select strategies for
improving preventive care performance. All of the inter-
vention practices implemented some form of a reminder
system as a strategy to improve performance. Eighteen
practice sites implemented a preventive care flow sheet;
two sites used a chart stamp; and two sites implemented a
computerized reminder system.
The facilitators provided management support to prac-
tices and followed a quality improvement framework sim-
ilar to that proposed by Leininger and colleagues [30]. For
each practice the facilitators were to: (1) present preven-
tive performance rates prior to the intervention, (2) facil-
itate the development of a practice policy for preventive
care, (3) assist in the setting of goals and desirable levels
of performance, (4) assist in the development of a written
plan for implementing preventive care, (5) assist in the
development and adaptation of tools and strategies to
implement the prevention plan, (6) facilitate meetings to
assess progress and modify the plan if necessary, and (7)
conduct performance feedback to measure the effect of
changes made.
The facilitators had no interaction with control practices.
The latter were told that they were involved in a study on
prevention but were not told which preventive manoeu-
vres were being measured. More details on the multi-com-
ponent nature of the intervention are published elsewhere
[35].
Setting
The Prevention Facilitator intervention involved Health
Service Organizations (HSOs) in Ontario. HSOs are com-
munity primary care practices that have a payment system
based primarily on capitation and not fee-for-service. At
the time of the study, there were 72 physician-sponsored
Table 1: Preventive manoeuvres studied
Level of Evidence Preventive Manoeuvre
AΩ  & B¥-categories: (Appropriate) 1. Folic acid for primary prevention of neural tube defects
2. Smoking cessation and nicotine replacement
3. Treatment for Hypertension
4. Mammography and exam in women over 50
5. STD screening for high risk groups
6. Papanicolaou smears for sexually active women
7. Influenza vaccination to patients 65 and older
8. Blood pressure measurement for patients 21 to 64 years of age
Dψ - category: (Inappropriate) 1. Proteinuria screening for general population
2. Blood glucose for the general population
3. Prostate-specific antigen testing for men over 50
4. Chest radiography
5. Mammography in women under 50
Ω  There is excellent evidence from repeated randomized controlled trials to support the manoeuvre.
¥ There is good evidence from cohort and case-control studies to support the manoeuvre.
ψ  Not recommended on the basis of fair evidence not to perform the manoeuvre.BMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
Page 4 of 15
(page number not for citation purposes)
HSOs located at 100 different sites in Ontario. The study
involved 106 physicians from 45 HSOs. All physicians
gave informed consent to participate in the trial.
Intervention outcomes
The goal of the intervention was to increase those preven-
tive manoeuvres supported by evidence as appropriate
and decrease those preventive manoeuvres supported by
evidence as inappropriate. Eight grade A and B, and 5
grade D preventive manoeuvres were chosen by a panel of
practicing family physicians from the Canadian Guide to
Clinical Preventive Health Care[3] to represent a broad
spectrum for both male and female adult patients (see
Table 1). The grade A and B manoeuvres are supported by
evidence as appropriate and the grade D manoeuvres are
supported by evidence as inappropriate. As determined by
chart audit, an absolute change overtime of 11.51% in
preventive care performance in favour of intervention
practices was achieved. More detailed outcome results of
the randomized controlled trial are reported elsewhere
[36].
We wanted to estimate the cost savings associated with an
effective outreach facilitation intervention designed to
reduce inappropriate and improve the delivery of appro-
priate preventive care.
Table 2: Demographic profile comparison of intervention and control practices
Measure Intervention Group (N = 22) Control Group (N = 23) Significance (P value)
Percentage of Group Practices 77.3% 60.9% .34
Percentage Teaching Affiliated 54.5% 52.2% 1.00
Percentage in communities greater than 50,000 86.4% 65.2% .17
Mean number of physicians in group practices 2.91 2.70 .71
Mean number of registered nurses in practices 1.16 1.64 .48
Mean year of graduation from medical school 1975 1975 .92
Mean proportion of female physicians 12.6 20.4 .37
Mean roster size 4317 3874 .55
Mean number of patients seen per day 34.4 33.0 .59
Percentage of female patients served 53.4 53.8 .89
Mean age of patients served 46.4 46.8 .87
Table 3: Comparison of intervention and control practices on delivery of preventive manoeuvres to eligible patients post intervention 
(N = 4501)
Preventive Manoeuvres Proportion of Eligible Patients
Intervention (n = 2201) Control (n = 2300) Significance
A & B Manoeuvres % (N) % (N)
Folic Acid Pre-conception 15.4% (325) 4.9% (369) .0001
Cessation Counselling 41.7% (571) 40.6% (549) N.S.
Mammography 50 to 69 68.3% (325) 57.5% (358) .005
Hypertension Treatment 79.7% (169) 82.7% (185) N.S.
STD Screening 23.3% (382) 19.1% (366) N.S.
BP Measurement 74.6% (1666) 72.5% (1781) N.S.
FLU Vaccination 66.0% (692) 53.8% (652) .0001
Cervical Cytology 66.2% (826) 60.2% (958) .01
D Manoeuvres
Blood glucose screening 32.8% (1844) 38.7% (1980) .0001
PSA Testing 30.6% (379) 30.0% (393) N.S.
Mammography 40 to 49 1 11.6% (267) 9.1% (309) N.S.
Chest X-Ray 3.7% (571) 4.9% (549) N.S.
Urine proteinuria screening 16.5% (1772) 29.8% (1887) .0001
1This was a grade D manoeuvre at the time of the study; the Canadian Task Force on Preventive Health Care has recently changed it to a Grade C 
manoeuvre.BMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
Page 5 of 15
(page number not for citation purposes)
Table 4: Input variables and cost estimates for appropriate manoeuvres (1999 dollars)
Variable Value and Rangea Source
A & B Manœuvres
Folic Acid
Difference in no. of eligible patients counseled 1495 (854, 2136) (36)
Probability of reducing neural tube defects .00058 (55)
Life-time treatment costs of Spina Bifida $201,822b (51)
Smoking Cessation Counselling/NRT
Difference in no. of eligible patients counseled 253 (-1072, 1577) (36)
Efficacy of NRT .06 (3)
Incidence of lung cancer in smokers .0024 (48)
Treatment costs for lung cancer $7,074 (56)
Mammography 50 to 69 years of age
Difference in no. of eligible women screened 1513 (505, 2521) (36)
Incidence of breast cancer .003165 (42)
Cost of a mammogram $76.54 (57)
Treatment costs saved for each breast cancer $2,522 (42)
Hypertension Treatment
Difference in no. of eligible patients treated -145 (-739, 449) (36)
Efficacy of treatment of stroke .42 (3)
Incidence of stroke .0018 (47)
Efficacy of treatment of heart disease .14 (3)
Incidence of heart disease .00196 (47)
Treatment cost per case for stroke $3,815 (56)
Treatment cost per case for heart disease $3,303 (56)
STD Screening
Difference in no. of eligible patients screened 645 (-253, 1542) (36)
Cost of gonorrhoeae and chlamydia culture $55 (57)
Incidence of gonorrhoeae or Chlamydia infection .08 (49)
Pelvic inflammatory disease (PID) prevented .14 (50)
Treatment cost per case for PID $1,782 (49)
Flu Vaccination
Difference in no. of eligible patients vaccinated 3364(1928,4799) (36)
Cost of flu vaccination $3.75 (43)
Pneumonia hospitalizations averted 4.1 per 1000 (43)
Chronic respiratory hospitalizations averted 10.4 per 1000 (43)
Congestive heart failure hospitalizations averted 2 per 1000 (43)
Emergency room visits avoided 21.6 per 1000 (43)
Emergency room visit cost $76.00 (44)
Cost of pneumonia hospitalization $4,462 (56)
Cost of chronic respiratory hospitalization $4,445 (56)
Cost of heart failure hospitalization $5,417 (56)
Cervical Cytology
Difference in no. of eligible patients screened 2196 (559, 3833) (36)
Cost of PAP test $57.17 (57)
Incidence of cervical cancer .00013 (46)
Treatment costs saved for each women screened $9,813 (41)
a 95% Confidence Intervals
b 10% discountBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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Methods
The analysis was part of a randomized controlled trial to
determine if outreach facilitation was effective in improv-
ing prevention in primary care. The design of the trial and
details of the method have been described in full else-
where [36]. Practices were randomized to either interven-
tion (22 practices) or control status (23 practices).
Patient eligibility
Patients eligible for the intervention were greater than 19
years of age, asymptomatic and had received the interven-
tion for screening and prevention purposes.
Cost analysis methodology
We performed a cost-consequences analysis to evaluate
the outreach facilitation intervention [37]. We deter-
mined the incremental costs of the preventive
manoeuvres performed and the overall cost of the inter-
vention. We estimated the cost-savings as a result of hav-
ing improved appropriate preventive care and reduced
inappropriate preventive care between intervention and
control conditions. All of the appropriate and inappropri-
ate preventive manoeuvres from the trial were included in
the analysis, not only those that showed significant
improvement. Multiple data sources were used to deter-
mine the costs of preventive procedures, treatment, and
efficacy of preventive manoeuvres (see Tables 4 and 5).
We determined the costs and savings associated with out-
reach facilitation by calculating the mean difference
between intervention and control groups in the number
of eligible patients screened or treated for appropriate pre-
ventive manoeuvres and the mean difference in the
number of eligible patients not screened for inappropriate
preventive care. The cost-consequences analysis is con-
ducted from the perspective of the Ontario Government.
All costs are presented on the basis of one year rather than
over the 18-month period of the intervention to corre-
spond with the government one-year planning and budg-
eting cycle. Costs were converted into Canadian dollars
using the nominal rate method and adjusted for inflation
(1999 current dollars) where necessary. The net cost sav-
ings per patient and per facilitator are presented.
Table 5: Input variables and cost estimates for inappropriate manoeuvres (1999 dollars)
Variable Value and Rangea Source
D Manoeuvres
Blood Glucose Screening
Difference in eligible patients not screened 4709 (2329,7089) (36)
Specificity of blood glucose test 89% (3)
Cost of fasting glucose test $10.34 (57)
Cost of glucose tolerance test $23.26 (57)
Cost of HgA1c $19.12 (57)
PSA Testing
Difference in eligible patients not screened 95 (-932, 1122) (36)
Cost of PSA Test $25 (57)
Specificity of PSA test 40% (3)
Cost of Biopsy* $232.83 (58)
Mammography 40 to 49
Difference in eligible patients not screened 295 (-296, 887) (36)
Cost of mammogram $76.54 (57)
Incidence of breast cancer .001616 (42)
Specificity of mammogram 96.5% (3)
Cost of Biopsy $2,164 (42)
Chest X-Ray
Difference in eligible patients not screened 276 (-271, 822) (36)
Cost of chest x-ray $233 (40)
Urine Proteinuria Screening
Difference in eligible patients not screened 9947 (7934,11961) (36)
Specificity of urine dipstick test 95% (3)
Cost of Urine culture and urinalysis $27.18 (57)
a 95% Confidence Intervals
*Includes intracavitary ultrasonography, ultrasound guidance of biopsy and needle biopsy of the prostateBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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Intervention costing methodology
The actual cost of the intervention over 18 months was
gathered from administrative expenditure records for
labour, supplies, telephone and travel. The investigation
team determined that the cost of training the nurse facili-
tators was important to include but that the investment in
training was worth more than the 18-month period of the
intervention. Therefore, the cost of the training of the
three nurse facilitators was depreciated over a 5-year life at
a discount rate of 5% using the double-declining balance
method for the 18-month period of the intervention. To
correspond with the government planning and budgeting
perspective, research costs were not included but supervi-
sion was. The justification for excluding research costs and
including supervision was to model the program as if it
were implemented as an actual government sponsored
intervention. As a government sponsored program there
would be no research salary and operations costs, but
there would still be the need to supervise the facilitators.
In addition, the cost of physician time for administering
preventive manoeuvres was not included. The rationale
for excluding physicians' time for administering preven-
tive manoeuvres is based upon the fact that the physicians
were not reimbursed on a fee-for-service basis but rather
were reimbursed on a capitation basis and the interven-
tion did not result in an increased number of visits keep-
ing costs the same in both the intervention and control
groups. Within a capitation based system, physicians are
reimbursed according to the size of their patient roster
and not by fee-for-service. Physicians within a capitation
based system do not receive additional fees for providing
preventive services, nor do they receive any additional
remuneration from seeing a patient more frequently.
Therefore, this is not an additional cost to the Ontario
provincial government.
Preventive manoeuvre costs
Using the most recent fee schedule for laboratory services,
published by the Ontario Ministry of Health in April of
1999, we calculated the direct costs of performing seven
appropriate and five inappropriate measures. Where cost
estimates were unavailable from these two sources, pub-
lished estimates for the cost of bilateral mammogra-
phy[38], administering a flu shot[39], a chest x-ray[40]
and cervical cancer screening[41]were used. The cost of
folic acid, nicotine replacement therapy, hypertensive
medication and antibiotics were not included since from
the perspective of the Ontario government we determined
that these costs would be substantially paid for directly by
patients. The measurement of blood pressure was
included as a case finding manoeuvre for hypertension as
described by the Canadian Task Force on Preventive
Health Care [3] but was not costed as 80% of eligible
patients in treatment and control groups received a blood
pressure measurement and as a consequence did not
impact the cost analysis. Calculations were performed
using Microsoft Excel Version 7.0.
Direct costs associated with inappropriate tests avoided
are considered savings to the government whereas the
costs associated with increasing the number of appropri-
ate tests are considered costs to the government (see
Tables 4 and 5). The direct cost for each inappropriate test,
according to the Ontario Ministry of Health, includes not
only the test cost for performing the manoeuvre but also
a "Patient Documentation and Specimen Collection Fee"
which can be applied to a test or series of tests performed
for one patient. The costs for appropriate tests were gath-
ered from the estimates of other relevant cost studies (see
Table 4). For the purpose of calculating costs, the total
population of 184,670 patients as of November 1998 for
all 45 HSO practices was used to estimate the total
number of intervention patients eligible (90,283) to
receive a test according to the patients eligible for the
selected tests from the study sample of 4,501 patients
(2,201 intervention patients, 2300 control patients).
The cost of the initial visit to the physician was not
included given that this cost would have been included
whether a test was performed or not and these costs would
be similar between the intervention and control groups
and thus would not significantly impact the cost analysis.
In addition, direct costs to the patient such as travel time
to a laboratory to have a blood test have not been
included. However, down-stream costs (follow-up visits
and further tests) for the subsequent follow-up of false
positive results for all screening manoeuvres where appro-
priate have been included. The down-stream costs
included the cost of biopsies to determine breast cancer
and prostate cancer as well as the cost of follow-up glu-
cose tolerance tests to screen for diabetes. Any down-
stream costs associated with other preventive manoeuvres
were not considered for the analysis.
The number of expected false positive screening tests was
determined from the specificity of a blood glucose test
(89%), a urine dipstick test for protienuria (95%), and a
PSA test (40%) [3]. A panel of five family physicians with
approximately 100 years of combined practice experience
determined through consensus the proportion of follow-
up tests and visits needed. For estimating the total costs of
performing follow-up on initially positive results for
blood glucose, it was agreed that 40% would receive only
a glucose tolerance test and 60% would receive both a
fasting blood glucose and an HgA1c. For estimating the
total costs of performing follow-up on positive urine pro-
tein tests, it was assumed that 100% of patients would
receive both a urine culture and a microscopic urinalysis
and a 24-hour urine. The documentation and specimen
collection fee of $7.75 was only included once for eachBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
Page 8 of 15
(page number not for citation purposes)
patient visit. For estimating the total costs of performing
follow-up on a positive PSA result, it was assumed that
90% of patients would be referred to an urologist [58].
The cost of family physician follow-up visits was not
included given that the HSO physicians were not reim-
bursed on a fee-for-service basis. The input variables and
cost estimates for appropriate and inappropriate manoeu-
vres are provided in Tables 4 and 5.
Preventive manoeuvre savings
The input variables and cost estimates for savings associ-
ated with preventive manoeuvres are provided in Tables 4
and 5. The difference in the number of patients receiving
preventive manoeuvres between the intervention and
control practices gave us the increase in savings to the gov-
ernment. Mammography can reduce breast cancer mortal-
ity by 20% to 30% [3]. For savings associated with
Mammography in women 50 to 69, Salzmann et al. [42]
was used to determine the difference in lifetime treatment
costs of screened and unscreened women with breast can-
cer. The estimated difference is $1,682 $US 1995 or con-
verted and inflated to 1999 dollars $2,522 $Can less for
the screened group. It is assumed that the incidence of
breast cancer in women 50 to 69 is 3.165 per thousand
[42].
For savings associated with administering flu vaccine in
the elderly, Nichol et. al.[43] provided the data on the
number of hospitalizations of the elderly averted due to
flu vaccination for pneumonia (4.1 per 1,000), chronic
respiratory conditions (10.4 per 1,000), congestive heart
failure (2 per 1,000) and the number of emergency room
visits avoided (21.6 per 1,000). The estimated cost of an
emergency room visit of $76.00 $Can 1999 as determined
by Jacobs and Hall was used [44]. The Ontario Case Cost-
ing project provided the average length of stay and the
total cost of hospitalization for pneumonia ($4,462 $Can
1999), chronic respiratory conditions ($4,445 $Can
1999) and congestive heart failure ($5,417 $Can 1999)
for patients 65 years of age and older.
Performing Pap tests every three years reduces invasive
cervical cancer by 91.2% [45]. Fahs et al. [46] provided the
cervical cancer incidence rate (10 per 100,000 women)
and Helms et al.[41] provided the difference in cervical
cancer treatment at stage of diagnosis. The difference
between the net costs of treatment for patients in the ini-
tial stages of cervical cancer and more invasive cancer is
$6,368 ($US 1988) or $9,813 ($Can 1999).
For determining savings associated with smoking cessa-
tion counselling and treatment of hypertension, the Cana-
dian Task Force on Preventive Health Care [3] provided
the percent efficacy of cessation counselling and the treat-
ment of hypertension for stroke and heart disease. The
Canadian Institute for Health Information [47] provided
the incidence of stroke and heart disease and Statistics
Canada provided the incidence of lung cancer in smokers
[48]. The Ontario Case Costing project provided the total
cost for lung cancer hospitalization ($7,074 $Can 1999),
stroke hospitalization ($3,815 $Can 1999), and hospital-
ization for heart disease ($3,303 $Can 1999) for deter-
mining overall treatment cost savings.
For savings associated with STD screening, Gift et. al.[49]
provided the figure for the incidence of gonorrhoeae or
chlamydia infection for eligible women as well as the cost
to treat a case of pelvic inflammatory disease (PID) and
the Centers for Disease Control and Prevention provided
the figure for the prevention of pelvic inflammatory dis-
ease from treatment [50].
Finally, for determining the costs averted as a result of
increasing folic acid intake, Waitzman et. al.[51] provided
the data on the net direct medical costs associated with
Spina Bifida ($123,485 $US 1996 or $201,822 $Can
1999) and the Canadian Task Force on Preventive Health
Care and the CDC provided the estimates for the reduc-
tion in neural tube defects due to folate, an estimated 50%
of all neural tube defects or 500 per million births [3].
After calculating the current (1999) cost of the interven-
tion and the cost of the increase in delivery of recom-
mended preventive manoeuvres we calculated the
potential direct savings to the government for increased
appropriate and decreased inappropriate preventive care
by multiplying the costs with the estimated difference in
patients screened or treated using the estimates and input
variables provided in Tables 4 and 5. We also calculated a
low and high estimate of costs using the 95% confidence
intervals of the difference in patients screened between
intervention and control groups. These calculations are
summarised mathematically in Appendix – [see Addi-
tional file 1].
Sensitivity analysis
To account for uncertainty in the cost-consequences anal-
ysis, a 1,000 iteration Monto Carlo simulation was con-
ducted to determine the impact of the range of input cost
parameters on the net savings to government using Micro-
soft Excel. The cost input parameters included the nor-
mally distributed range of values between the 95%
confidence intervals for percent difference between inter-
vention and control practices on the preventive manoeu-
vre performance outcomes. These parameters are
considered the most important in influencing overall
costs and cost savings in the analysis. The ranges of ran-
domly chosen estimates of each parameter were varied
simultaneously to determine the impact on costs and cost
savings. Finally, the ranges of input parameters wereBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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assessed individually on the ranges of the net savings out-
come generated by the simulation to generate a Tornado
diagram. Percent variance was used to determine the
degree to which the outcome net savings was sensitive to
the values of each input parameter and to determine
which input parameter had the greatest impact on net
savings.
Results
Intervention (n = 22) and control (n = 23) group practices
did not differ significantly on any of the demographic
characteristics presented in Table 2.
Intervention effect
Table 3 presents the proportion of eligible patients that
received recommended (A & B Manoeuvres) and inappro-
priate (D Manoeuvres) preventive care for both interven-
tion and control groups of patients after the outreach
facilitator intervention.
For inappropriate testing there was a statistically signifi-
cant but small reduction in the proportion of eligible
patients that received a random blood glucose test to
screen for diabetes (32.8% vs. 38.7%) and a larger reduc-
tion for urine protein testing to screen for kidney disease
(16.5% vs. 29.8%). There were no significant differences
for PSA testing to screen for prostate cancer, mammogra-
phy for women 40 to 49, or chest radiography to screen
for lung cancer in smokers. For appropriate preventive
manoeuvres there was a statistically significant difference
for folic-acid counselling, mammography for women 50
to 59, flu vaccination, and cervical cytology.
Intervention costs
Table 6 provides data on the costs of the outreach facilita-
tor intervention in 1999 dollars. The 18-month
intervention cost a total of $357,583.00 for three nurse
facilitators including all travel, telephone, supplies and
supervision or $238,388 per year. Telephone costs include
the cost of a cellular phone as well as the long distance
costs of a home telephone. Supply costs include the costs
of home-office supplies as well as the cost of materials for
intervention purposes in the practices. The cost of the
intervention on a yearly basis equates to $10,835 per
intervention practice (n = 22) or $4,584 per intervention
physician (n = 52) or $328 per visit based on an average
of 33 visits to the practice per year.
Table 7 provides the costs of providing recommended pre-
ventive care. The intervention resulted in 1,513 more
mammograms having been done which is estimated to be
an additional cost to the government of $77,192 per year
with a range of $25,743 to $128,641 depending on the
number of mammograms. 645 additional cultures for
gonorrhoeae and chlymadia were carried out in the inter-
vention arm resulting in an estimated $23,631 in costs. In
addition, 3,364 more flue shots were provided in the
intervention arm of the trial costing $8,409 per year and
2,196 more women received a PAP test at a cost of
$83,679 per year (see Table 7).
The total cost to the government for the intervention and
additional manoeuvres performed was $431,300 (95%
CI: $280,969 – $581,630) on a yearly basis, that equates
to $19,604 per intervention practice, or $143,766 per
facilitator or $4.67 per HSO patient rostered (see Table
10).
Cost savings
Table 8 gives the estimated cost savings in 1999 dollars as
a result of having significantly reduced inappropriate care
in the intervention group for unrecommended screening
manoeuvres. For the laboratory and diagnostic services
cost model extrapolated to the entire eligible patient ros-
ter for intervention practices there is an estimated
$148,568 (95% CI: -$175,898 – $473,035) in total sav-
ings including follow-up tests. This represents 34% of the
costs of the outreach facilitator intervention and reduces
the program to a cost of $282,732.
Table 9 provides the cost savings to the government as a
result of averted hospitalizations and treatment costs.
There is an estimated $455,464 (95% CI: $237,935 -
$672,992) per year in averted hospitalization and treat-
ment costs as a result of increasing the provision of
recommended care to eligible patients. Most of the cost
averted ($254,633 per year) is due to the estimated reduc-
tion in hospitalizations for pneumonia [14], acute
chronic respiratory conditions [35], and cases of conges-
tive heart failure [7]. The treatment costs saved of an esti-
mate of one case of Spina Bifida equated to $174,999.
Costs averted due to hospitalizations and treatment
equate to $20,703 per practice, $151,821 per facilitator,
and $4.93 per patient.
Table 6: Intervention costs over 12 months
Cost Item 1999 Dollars
Staff training $20,450
Salaries & Benefits $178,200
Supplies $7,060
Telephone $8,629
Car Mileage & Insurance $12,049
Supervision $12,000
INTERVENTION COST $238,388BMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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Table 7: Costs associated with the increase of appropriate preventive manoeuvres (1999 Dollars)
Manoeuvre Baseline Low High
STD Screening $23,630.87 -$9,268.28 $56,530.01
Mammography 50 to 59 $77,192.11 $25,742.87 $128,641.34
Influenza shot $8,409.23 $4,820.83 $11,997.62
Pap Test $83,679.41 $21,286.01 $146,072.81
TOTAL $192,911.62 $42,581.43 $343,241.78
Table 8: Savings associated with the reduction of inappropriate preventive care (1999 Dollars)
Manoeuvre Baseline Low High
Chest X-Ray $42,827.36 ($42,065.12) $127,719.83
Mammography 40 to 49 $16,107.12 ($16,131.58) $48,345.82
PSA Testing $16,125.11 ($158,156.15) $190,406.37
Blood glucose $59,990.54 $29,672.59 $90,308.49
Urine Protein $13,518.31 $10,782.33 $16,254.29
TOTAL $148,568.44 ($175,897.93) $473,034.80
Table 9: Savings from the provision of appropriate preventive care (1999 Dollars)
Condition Baseline Low High
Breast Cancer $12,075.20 $4,026.97 $20,123.44
Influenza $254,633.54 $145,976.01 $363,291.07
Neural Tube Defects $174,999.39 $99,997.21 $250,001.56
Cervical cancer $2,154.49 $548.05 $3,760.92
Lung Cancer $122.27 ($518.51) $763.06
Heart Disease ($808.13) ($4,116.12) $2,499.86
STD Treatment $12,862.75 ($5,044.91) $30,770.42
Stroke ($575.90) ($2,933.28) $1,781.48
TOTAL $455,463.61 $237,935.42 $672,991.81
Table 10: Estimated cost savings
Baseline Low High
Costs
Intervention Cost $238,388 $238,388 $238,388
Manoeuvre Costs $192,911.62 $42,581.43 $343,241.78
Total Costs $431,299.62 $280,969.43 $581,629.78
Savings
Inappropriate manoeuvre savings $148,568.44 ($175,897.93) $473,034.80
Treatment cost savings $455,463.61 $237,935.42 $672,991.81
Total Savings $604,032.05 $62,037.49 $1,146,026.61
NET Savings $172,732.44 ($218,931.95) $564,396.83BMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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Table 10 shows that the cost of the program over one year
combined with the increased costs associated with deliv-
ering more recommended preventive care is $431,300.
The costs averted from reducing inappropriate tests and
the reduction in hospitalization and treatment are
$604,032. This is a net cost savings to the government of
$172,732 (95% CI: -$218,932 – $564,397) per year as a
result of the intervention with 22 practices and equates to
$1.87 per patient saved or $3,321 per physician, an esti-
mated return on the intervention and investment in addi-
tional manoeuvres of 40%. Based on a Consumer Price
Index of $1.11 the net cost savings to the government in
2003 dollars are $191,733 per year or $8,715 per practice,
$3,687 per physician, or $2.08 per patient.
Sensitivity analysis
The sensitivity analysis using Monte Carlo simulation
revealed that the mean net savings in 1999 dollars to the
government would be $175,510 and that 90% of the
expected net savings to the government would fall
between $-43,000 and $394,000 (see Figure 1). Based
upon 1,000 iterations of the cost model and the assump-
tions regarding input costs, it is unlikely that the govern-
ment would not receive some return on its investment in
outreach facilitation. Finally, Figure 2 shows the relation-
ship between each of the input variables to net savings. As
would be expected net savings is very sensitive to PSA test-
ing with the more men tested the less net savings account-
ing for 47.4% of the variance. Flu vaccination also impacts
net savings in terms of pneumonia prevented and
accounting for 18.4% of the variance in net savings. Due
to the poor specificity of the PSA test and the non signifi-
cant effect of the intervention to reduce PSA tests in eligi-
ble men, the cost associated with the PSA test varies
considerably and its reduction is critical for attaining cost
savings whereas the increase of PSA tests is negatively
associated with savings. In contrast, PAP testing and mam-
mography for 50 to 59 year old women in the cost model
are not as negatively associated with net savings despite
the increase in costs as more of these manoeuvres are
performed.
Discussion
The primary objective of this study was to determine if
decreasing inappropriate preventive tests and increasing
appropriate testing performance could offset the cost of
an outreach facilitation intervention to improve preven-
tive practice. The significant reduction in inappropriate
testing and increase in appropriate testing resulted in net
savings of $191,733 per year in 2003 dollars to the gov-
ernment or a return on investment of 40%. The limita-
tions of the cost analysis are typical to this type of
economic evaluation [37]. They include:
Distribution of outcome for net savings Figure 1
Distribution of outcome for net savingsBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
Page 12 of 15
(page number not for citation purposes)
• the perspective of the government necessitated not hav-
ing included all possible costs in the model. For example,
the cost for patient time, travel or patient discomfort and
anxiety associated with the manoeuvre were not included;
• the total indirect costs associated with hospitalizations
averted were not included;
• the estimate of the frequency of downstream events was
based on a panel of experts;
• the estimate for screening for cervical cancer was based
on a yearly screening rather than once every three years;
• downstream costs were estimated and included in the
model for follow-up visits as a result of a false positive test
only. Other possible downstream costs such as visits to
other allied health professionals or consults to specialists
were not included;
• the benefit of inappropriate screening tests for some
patients and the associated cost savings have been
ignored; and
• rates of delivery for preventive screening tests were from
a randomized controlled trial in a HSO setting. Therefore,
caution must be used when generalizing the potential cost
savings to other settings.
Sensitivity analysis for net savings Figure 2
Sensitivity analysis for net savingsBMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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Our cost estimates in this analysis are conservative since
patient costs and other downstream costs were not
included. Nonetheless, the analysis shows that all of the
costs of the outreach facilitator intervention can be
recouped as a result of having reduced inappropriate test-
ing and increased appropriate testing for the manoeuvres
under study. Similarly, McCowan et. al. were able to show
that a facilitation intervention was able to improve pri-
mary care asthma management and that the cost savings
to the health care system could completely offset the
annual salary of one facilitator serving a large number of
family physicians [28]. McCowan's study also included
the costs associated with hospital admissions and second-
ary costs and involved the improvement in treatment of
an acute illness and not prevention in primary care.
Including the downstream costs associated with inappro-
priate tests averted for the outreach facilitator intervention
has allowed for an additional 35% in estimated cost sav-
ings and the inclusion of costs averted associated with
appropriate testing has completely offset the cost of out-
reach facilitation.
The successful outreach facilitator intervention described
in this study was a very intensive intervention with each
practice being visited an average of 33 times over 18
months. This compares to other successful trials such as
Dietrich et. al. [23] where outreach facilitators visited only
3 times over a three-month period at an average of 120
minutes per visit and Hulscher et. al. [32] where facilita-
tors visited practices an average of 25 times with an aver-
age duration of only 73 minutes. Both of these studies
used outreach facilitation to improve preventive practice
for a number of different maneuvres. Unfortunately, the
cost of outreach facilitation was not included in these less
intensive studies.
The cost of an outreach facilitator in our study per year
was over $4,497 per physician but resulted in an overall
net savings to the government of $3,289 per physician. In
comparison, Cockburn et. al. tested an educational out-
reach facilitator intervention to improve physician smok-
ing cessation counselling performance which cost $A142
in 1992 per practitioner [27]. However, the facilitator
only visited each physician twice at an average of 12 min-
utes per visit or $A72 per visit and achieved very little in
the way of improved outcomes. As a consequence, unsuc-
cessful outreach facilitation was shown to be not cost-
effective compared to other alternatives. In our interven-
tion the cost per visit was $590 and nothing after having
adjusted for cost savings associated with a successful inter-
vention. Our intervention was targeted at changing the
entire practice and not just physician behaviour for a
number of preventive measures, and as a result more time
was spent on-site and more visits were required. More
research is necessary to determine the most appropriate
intensity of intervention for a given level of outcome.
The Cochrane Effective Practice and Organization of Care
Group has compiled evidence that supports outreach vis-
its combined with additional interventions as effective in
improving professional practice and health outcomes
[13]. Our study has demonstrated the effectiveness of
outreach facilitation in improving overall preventive care
performance. This is the first cost-consequences analysis
of an outreach facilitation intervention that we are aware
of and we have shown that the savings attributable to the
reduction in inappropriate testing and increases in appro-
priate testing can offset all of the intervention cost and in
fact result in a net savings to the government of approxi-
mately two dollars for every rostered patient. Further, the
sensitivity analysis has revealed that the likelihood of net
savings to the government is substantial despite variation
in the inputs. However, it has also revealed that the
appropriate primary preventive manoeuvres such as vacci-
nation of the elderly contribute more to net savings to the
government than some secondary preventive manoeuvres
such as Pap testing and mammography. The net savings
associated with primary prevention help to cover the net
costs to the government associated with secondary pre-
vention. As well, in the case of PSA testing even greater
cost savings may be possible by significantly reducing this
and other inappropriate tests and the consequent down-
stream costs.
Filak et. al. [52] calculated the lifetime charges of office
visits, procedures, laboratory tests, and patient purchases
required to comply with the US Preventive Services Task
Force screening recommendations. They determined that
the lifetime charges in 1999 US Dollars for all required
preventive services ranged from $5,432.60 to $7,529.60
for men and from $15,307.10 to $18,525.10 for women.
If physicians could deliver all the necessary preventive
care to their patients, the costs over a lifetime are very rea-
sonable in comparison to all of the costs associated with
treating a stage I ($14,000) or stage IV ($64,000) cancer of
the breast in a woman over 50 [53] or a case of pneumo-
nia ($35,700) caused by influenza in a person 65 years
old [54]. The outreach facilitator intervention was effec-
tive in improving the uptake of preventive manoeuvres
shown to be very cost-effective with the added benefit of
reducing preventive manoeuvres that are less cost-effec-
tive. If the estimated 9,850 family physicians in Ontario
received the benefit of outreach facilitation, the estimated
savings to the government equate to $36.3 million (2003
dollars). However, this study involved HSO physicians
who may not be representative of all family physicians
and research has demonstrated that the intervention does
not work in chaotic practices [59].BMC Health Services Research 2005, 5:20 http://www.biomedcentral.com/1472-6963/5/20
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Conclusion
This paper has provided information on the cost of out-
reach facilitation and the potential for cost savings to the
health system. The results can be considered an underesti-
mate of the true potential cost savings given that not all
the costs associated with inappropriate and appropriate
preventive care were considered. Further, this was an effi-
cacy trial and as a consequence there is potential for
reducing the cost of the intervention through efficiency
improvements such as increasing the number of practices
per facilitator as well as savings in administration and
training through economies of scale. In addition, addi-
tional savings to the health system may be possible
through on-going outreach facilitation for chronic illness
care.
There are no magic bullets to changing primary care prac-
tice patterns [9]. However, a facilitation approach that
incorporates a number of intervention strategies tailored
to the environment and needs of the practice holds prom-
ise. The literature has shown that outreach facilitation is
one of the most effective means of improving the delivery
of primary care preventive health services [13]. Further
economic evaluations of outreach facilitation and other
intervention alternatives are needed to assist in important
public policy and administrative decision-making on get-
ting preventive care guidelines into practice.
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